LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Lista de Ações・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Fechado

17.26 3.23

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

16.47

Máximo

17.52

Indicadores-chave
By Trading Economics
Rendimento	-6.4M -20M
Vendas	-807K 71M
EPS	-0.13
Margem de lucro	-28.24
Funcionários	624
EBITDA	-7.9M -14M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+19.35% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	121M 2.4B
Abertura anterior	14.03
Fecho anterior	17.26

Adaptive Biotechnologies Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de jun. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 de jun. de 2026, 23:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 de jun. de 2026, 23:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 de jun. de 2026, 22:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 de jun. de 2026, 20:51 UTC

Ganhos

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 20:09 UTC

Conversa de Mercado

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 de jun. de 2026, 19:36 UTC

Conversa de Mercado

Cattle Climbs as Crude Oil Falls -- Market Talk

9 de jun. de 2026, 19:32 UTC

Conversa de Mercado

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 de jun. de 2026, 19:25 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 de jun. de 2026, 19:00 UTC

Conversa de Mercado

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 de jun. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 de jun. de 2026, 18:47 UTC

Conversa de Mercado

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 de jun. de 2026, 18:37 UTC

Conversa de Mercado

Canada's Cooling Trade With the U.S. -- Market Talk

9 de jun. de 2026, 18:27 UTC

Conversa de Mercado

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 de jun. de 2026, 17:35 UTC

Conversa de Mercado

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 de jun. de 2026, 17:30 UTC

Conversa de Mercado

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 de jun. de 2026, 16:34 UTC

Conversa de Mercado

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

9 de jun. de 2026, 15:28 UTC

Conversa de Mercado

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 de jun. de 2026, 15:25 UTC

Conversa de Mercado

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparação entre Pares

Variação de preço

Adaptive Biotechnologies Corp Previsão

Preço-alvo

By TipRanks

19.35% parte superior

Previsão para 12 meses

Média 20.17 USD 19.35%

Máximo 22 USD

Mínimo 18 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Adaptive Biotechnologies Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Adaptive Biotechnologies Corp - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.